Iopofosine I 131 (CLR 131)
Relapsed/Refractory Multiple Myeloma
Key Facts
About Cellectar Biosciences
Cellectar Biosciences is a clinical-stage oncology company leveraging its proprietary Phospholipid Drug Conjugate (PDC) platform to develop targeted therapeutics for cancer. Its lead asset, iopofosine I 131, is in late-stage development for relapsed/refractory multiple myeloma and other hematologic malignancies, representing a potential first-in-class targeted radiotherapeutic. The company's strategy is to exploit the unique lipid metabolism of cancer cells to deliver diverse payloads with precision, thereby improving therapeutic indices. Despite its innovative platform, Cellectar operates with a micro-cap valuation, reflecting the high-risk, binary nature of its late-stage clinical programs.
View full company profileAbout Cellectar Biosciences
Cellectar Biosciences is a clinical-stage oncology company leveraging its proprietary Phospholipid Drug Conjugate (PDC) platform to develop targeted therapeutics for cancer. Its lead asset, iopofosine I 131, is in late-stage development for relapsed/refractory multiple myeloma and other hematologic malignancies, representing a potential first-in-class targeted radiotherapeutic. The company's strategy is to exploit the unique lipid metabolism of cancer cells to deliver diverse payloads with precision, thereby improving therapeutic indices. Despite its innovative platform, Cellectar operates with a micro-cap valuation, reflecting the high-risk, binary nature of its late-stage clinical programs.
View full company profileTherapeutic Areas
Other Relapsed/Refractory Multiple Myeloma Drugs
| Drug | Company | Phase |
|---|---|---|
| Aplidin (plitidepsin) | PharmaMar | Approved (Conditional - AU) |
| TECVAYLI + DARZALEX FASPRO | johnson-and-johnson-innovative-medicine | Approved |
| Linvoseltamab | Regeneron | Phase 3 |
| Blenrep (belantamab mafodotin) | GSK | Phase III |
| CAR T-Cell Therapy Program | Dr. Reddy's Laboratories | Development |
| HDP-101 | Heidelberg Pharma | Phase I/IIa |
| inobrodib + Pd (InoPd) | CellCentric | Phase 1/2 |
| CT053 | CARsgen Therapeutics | Phase Ib/II |
| CT059 | CARsgen Therapeutics | Phase I |
| P-BCMA-ALLO1 | Poseida Therapeutics | Phase 1 |
| P-BCMA-101 | Poseida Therapeutics | Phase 1/2 |
| ABBV-383 | AbbVie | Phase 1 |